Nanoviricides Story

<div class='circular--portrait' style='background:#9CBEFD;color: #ffffff;font-size:5em;'>N</div>
NNVC -- USA Stock  

USD 4.18  0.05  1.21%

It appears NanoViricides Inc will continue to recover much faster as its share price surged up 15.67% today. The company current daily volatility is 4.22 percent, with a beta of 0.25 and an alpha of 0.22 over DOW. As many investors are getting excited about business services, it is fair to go over NanoViricides Inc NEW. We will look into some reasons why it is still possible for NanoViricides Inc to maintain above-average margins while minimizing volatility.
Published over a month ago
View all stories for Nanoviricides | View All Stories
How risky is NanoViricides Inc NEW after the current volatility rise?
NanoViricides Inc NEW currently holds roughly 21.79 M in cash with (7.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.04. We provide investment recommendation to complement the last-minute expert consensus on NanoViricides Inc NEW. Our dynamic recommendation engine harnesses a multidimensional algorithm to analyze the entity's potential to grow using all technical and fundamental data available at the time.
Investing in Nanoviricides, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Nanoviricides along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Nanoviricides' stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Nanoviricides in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Nanoviricides. Your research has to be compared to or analyzed against Nanoviricides' peers to derive any actionable benefits. When done correctly, Nanoviricides' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Nanoviricides.

How important is Nanoviricides's Liquidity

Nanoviricides financial leverage refers to using borrowed capital as a funding source to finance Nanoviricides ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Nanoviricides financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Nanoviricides's total debt and its cash.

How Nanoviricides utilizes its cash?

To perform a cash flow analysis of Nanoviricides, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Nanoviricides is receiving and how much cash it distributes out in a given period. The Nanoviricides cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Nanoviricides Net Cash Flow from Operations is projected to decrease significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at (6 Million)

Nanoviricides Correlation with Peers

Investors in Nanoviricides can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in Nanoviricides. Diversification will allow for the same portfolio return with reduced risk. The correlation table of Nanoviricides and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities Nanoviricides is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage.
Please check volatility of Nanoviricides for more details

Payment of 38472 shares by Eugene Seymour of NanoViricides Inc subject to Rule 16b-3

Legal trades by Nanoviricides insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
NanoViricides insider trading alert for payment of common stock par value $0.001 per share by Eugene Seymour, Chief Executive Officer, on 14th of December 2020. This event was filed by Nanoviricides Inc with SEC on 2015-09-24. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Another angle On Nanoviricides

NanoViricides Inc appears to be moderately volatile, given 1 month investment horizon. NanoViricides NEW has Sharpe Ratio of 0.0679, which conveys that the firm had 0.0679% of return per unit of risk over the last month. Our standpoint towards estimating the volatility of a stock is to use all available market data together with stock specific technical indicators that cannot be diversified away. We have found twenty-eight technical indicators for NanoViricides Inc, which you can use to evaluate future volatility of the firm. Please exercise NanoViricides Inc NEW Downside Deviation of 3.16, mean deviation of 2.76, and Risk Adjusted Performance of 0.0732 to check out if our risk estimates are consistent with your expectations.
DMAC
NK
DTIL
DRNA
EDIT
DMAC
0.920.410.30.95
DMAC
NK
0.920.50.340.89
NK
DTIL
0.410.50.550.25
DTIL
DRNA
0.30.340.550.22
DRNA
EDIT
0.950.890.250.22
EDIT
DMAC
NK
DTIL
DRNA
EDIT
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Can NanoViricides Inc build up on the current rise?

Current downside variance is at 10.0. NanoViricides Inc NEW shows above-average downside volatility for the selected time horizon. We advise investors to inspect NanoViricides Inc NEW further and ensure that all market timing and asset allocation strategies are consistent with the estimation of NanoViricides Inc future alpha.

The Bottom Line

Whereas some other firms within the biotechnology industry are still a little expensive, even after the recent corrections, NanoViricides Inc may offer a potential longer-term growth to investors. The inconsistency in the assessment between current NanoViricides valuation and our trade advice on NanoViricides Inc is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to NanoViricides Inc.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Nanoviricides. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com